Acute From Leukemia Myeloid Remission

Acute From Leukemia Myeloid Remission Article

Chronic myelogenous leukemia Classifications and external resources The Philadelphia chromosome as seen by metaphase FISH. ICD-10 C92.1 ICD-9 205.1 ICD-O: M9863/3 DiseasesDB 2659 MedlinePlus 000570 eMedicine med/371

Acute From Leukemia Myeloid Remission News

Combination Chemotherapy May Produce Remission in Adults With Acute Myeloid Leukemia, According to Interim Findings.

PHILADELPHIA - A novel chemotherapy regimen that combines standard drugs with an antibody-targeted agent has shown early success in treating adults with acute myeloid leukemia, according to preliminary data from a multicenter study led by researchers at Dana-Farber Cancer Institute in Boston. The

Phase 2 Study of Genasense Plus Mylotarg Yields Complete Remissions in Older Patients With Acute Myeloid Leukemia.

Separate Study Shows Remission in AML Correlates With Biomarkers of Cellular Target and Drug Content Genta Incorporated today announced that results have been reported from two clinical studies using Genasense(R) (oblimersen sodium) Injection, the Company's lead anticancer compound, in combination

Combination Chemotherapy May Produce Remission in Adults With Acute Myeloid Leukemia, Interim Findings Suggest.

Byline: Dana-Farber Cancer Institute PHILADELPHIA, Dec. 10 (AScribe Newswire) - A novel chemotherapy regimen that combines standard drugs with an antibody-targeted agent has shown early success in treating adults with acute myeloid leukemia, according to preliminary data from a multicenter study

Maxim Reports That Additional Phase 3 Trial of Ceplene Therapy in the Treatment of Acute Myeloid Leukemia Patients in Complete Remission Will Be Required by the FDA.

SAN DIEGO - Company Continuing Discussions with European Regulators Regarding AML Application Maxim Pharmaceuticals, Inc. (Nasdaq:MAXM)(SSE:MAXM) today announced that based on ongoing correspondence with the United States Food and Drug Administration (FDA), as well as consultations with external

Seattle Genetics Reports Multiple Complete Remissions With SGN-33 in Acute Myeloid Leukemia at ASH.

Single-Agent Administration of SGN-33 Results in Seven Objective Responses Out of Seventeen AML Patients Treated in Phase Ia Dose-Escalation Clinical Trial SEATTLE - Seattle Genetics, Inc. (Nasdaq:SGEN) today announced positive data from a phase Ia clinical trial of SGN-33 (lintuzumab)